Intranasal trimeric sherpabody COVID-19 therapeutic - Pandemblock
Alternative Names: Covidin - Pandemblock; COVIDIN nasal spray - Pandemblock; TriSb92 - PandemblockLatest Information Update: 23 Oct 2023
At a glance
- Originator University of Helsinki
- Developer Pandemblock
- Class Antivirals; Recombinant proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 23 Oct 2023 Intranasal trimeric sherpabody therapeutic is available for licensing as of 23 Oct 2023. https://pandemblock.com/partnering (Pandemblock website, October 2023)
- 23 Oct 2023 Preclinical trials in COVID-2019 infections (Prevention) in Finland (Intranasal) prior to October 2023 (Pandemblock pipeline, October 2023)
- 23 Oct 2023 Preclinical trials in COVID-2019 infections in Finland (Intranasal) prior to October 2023 (Pandemblock pipeline, October 2023)